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ABSTRACT
Introduction: Infections due to extended-spectrum beta-lactamase (ESBL)-producing isolates in patients are 
hard to treat and cause high morbidity and mortality. ESBL-producing bacteria have been increasingly detected 
in environmental samples in different countries since 2002, and have gained considerable attention worldwide.
Methods: Antibiotic susceptibility of all isolates was determined using the disk diffusion method. The 
production of ESBLs was determined by the double-disk synergy test.
Results: Among the outpatient clinical samples, out of 2857 Gram-negative bacteria, 184 (6.5%) ESBL-
producing bacteria were isolated. In this group, 143 (77.7%) were from urine samples, 26 (14.1%) from surgi-
cal wounds, 6 (3.3%) from umbilical swabs, and 9 (4.9%) from other patients sites (upper respiratory tract, can-
nula, eyes, genital swabs). Escherichia coli was isolated in 62 (33.7%), and Klebsiella spp. in 50 (27.8%) cases. 
Among the environmental samples, out of 381 Gram-negative bacteria, 52 (13.6%) were ESBL-producing iso-
lates. In this group, 37 (71.2%) were sampled from water, 7 (13.5%) from food, and 8 (15.4%) from environ-
mental surfaces. The most prevalent ESBL-producing bacteria isolated from the environmental samples were 
E. coli (isolated from 26 samples), Klebsiella spp. (10), non-fermenters (9), and other bacteria isolated from 
7 samples. The clinical outpatient ESBL-producing isolates showed resistance to all cephalosporins, ranging 
from 25% (cefepime) to 100% (cefuroxime). The environmental ESBL-producing isolates showed resistance to 
cefuroxime, aztreonam, cefpodoxime, amoxicillin/clavulanate, and cefoxitin in the range of 65-100%.
Conclusions: Prevalence of antibiotic resistance of ESBL-producing strains is high and requires routine 
detection of ESBL-producing isolates in the laboratories, designing of appropriate antibiotic prescribing 
policies and control of the risk factors.
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INTRODUCTION
Over the past decades, antimicrobial resistance 
has been recognized as an important global health 
problem in many fields, such as human and veter-
inary medicine, livestock holdings, agriculture, and 
environment (1,2). In countries with low social 
and economic status, especially countries in South 
and Southeast Asia, antimicrobial resistance is more 
prevalent (3). The production of extended-spec-
trum beta-lactamases (ESBLs) or AmpC beta-lact-
amases is one of the most important mechanisms 
of resistance to extended-spectrum cephalosporins 
in the Gram-negative isolates (4). ESBLs are plas-
mid encoded enzymes and their genes are usually 
transported by plasmids. The enzymes are capable 
of inactivating a large number of beta-lactam anti-
biotics, including an extended spectrum and a very 
broad spectrum cephalosporins and monobactams. 
The overexpression of chromosomal or plasmid-me-
diated AmpC enzymes in patients can cause resis-
tance to broad spectrum cephalosporins (5).
In the past decades, the ESBLs were mostly associ-
ated with hospitals and institutional care in humans, 
but they are now increasingly found in the commu-
nity, in food producing animals, and in water (6-8). 
They have been detected in food for animals at 
farms, meat, water, and the environment in many 
countries such as Italy, China, Malaysia, Nigeria, 
Austria, and the Netherlands (5,9-14).
Investigations of prevalence and antibiotic resistance 
in Bosnia and Herzegovina (B&H) are scarce. ESBLs 
and AmpC beta-lactamases have been reported in 
isolates causing urinary tract infections and noso-
comial infections in the Zenica-Doboj Canton and 
Tuzla Canton (6,15).
The aim of this study was to investigate the preva-
lence and antibiotic resistance of ESBL-producing 
isolates in the Zenica-Doboj Canton, B&H.
METHODS
Setting, bacterial isolates, and study design
Between December 2009 and May 2010, and 
between December 2013 and May 2014, a 
random sample of 184 clinically relevant and 
non-duplicate isolates was routinely collected in 
the Microbiology Laboratory at the Cantonal 
Hospital Zenica. The Cantonal Hospital Zenica 
is 849 bed tertiary level hospital admitting about 
25 000 patients/year, with 240 000 hospital days, 
and covers a population of 331 229 in the Zenica-
Doboj Canton.
The institutional review board approval from the 
Ethics Committee of the Cantonal Hospital Zenica 
was obtained prior to the initiation of the study.
Between December 2013 and May 2014, a random 
sample of 52 Gram-negative isolates from environ-
mental samples was collected in the Microbiology 
Laboratory of the Institute for Public Health and 
Food Safety in Zenica.
The environmental and clinical samples were ana-
lyzed according to the International Standardization 
Organization standards.
Antimicrobial susceptibility testing
The susceptibility testing to 13 antimicrobials was 
performed by a two-fold microdilution technique 
according to the Clinical and Laboratory Standards 
Institute (CLSI) procedure (16). Escherichia coli 
ATCC 25922 (ESBL negative) and Klebsiella pneu-
moniae 700603 (ESBL positive) were used as quality 
control strains.
Phenotype detection of ESBLs
ESBL production was determined by the double 
disk-synergy test (DDST). Overnight broth culture 
of the test strain was diluted in saline, adjusted to 
McFarland standard suspension 0.5 and inoculated 
onto Mueller-Hinton agar (MHA); disk contain-
ing amoxicillin/clavulanate (20/10  µg) was placed 
in the middle of the plate and surrounded (20 mm 
distance center to center) by disks containing cefo-
taxime (5  µg), ceftriaxone (30  µg), ceftazidime 
(10 µg), and cefepime (30 µg) (Becton-Dickinson, 
USA). Plates were incubated overnight at 37 °C. 
Any distortion or increase of the inhibition zones 
around cephalosporin disks toward amoxicillin/
clavulanate disk was indicative of ESBL produc-
tion (16). Production of ESBLs was confirmed by 
CLSI combined disk test. Disks containing 30 µg 
of cefotaxime and ceftazidime, and disks containing 
a combination of the two drugs plus 10 µL (10 µg) 
of clavulanic acid (Becton-Dickinson, USA) were 
placed independently, 20  mm apart, on a lawn 
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culture of 0.5 McFarland opacity of the test isolate 
on the Mueller-Hinton agar plate and incubated for 
18-24 hours at 35°C. Isolates were considered ESBL 
positive if the inhibition zone measured around 
one of the combination disks after the overnight 
incubation was at least 5  mm larger than that of 
the corresponding cephalosporin disk (16). Isolates 
resistant to the extended-spectrum cephalosporins 
and β-lactam/β-lactamase inhibitor combination 
(amoxicillin/clavulanic acid) were screened for the 
production of AmpC β-lactamases by the com-
bined disk test using 3-amino phenylboronic acid 
(PBA) (Sigma-Aldrich, Steinheim, Germany). The 
stock solution was prepared as previously recom-
mended (17) by dissolving PBA (benzeneboronic 
acid; Sigma-Aldrich, Steinheim, Germany) in 
dimethyl sulfoxide at a concentration of 20 mg/mL. 
Twenty µL (containing 400 µg of boronic acid) of 
the solution was dispensed onto antibiotic disks. 
The disks were then dried and used within 60 min. 
The tests were performed by inoculating Mueller-
Hinton agar by the standard diffusion method and 
placing disks containing four different β-lactams 
(CAZ, 10 µg; CRO, 30 µg; CTX, 5 µg; FEP, 30 µg) 
with or without boronic acid. The agar plates were 
incubated at 37°C overnight. The diameter of the 
growth-inhibitory zone around a β-lactam disk with 
boronic acid was compared to the zone around the 
corresponding β-lactam disk without boronic acid. 
The test was considered positive for the detection 
of AmpC production when the diameter of the 
growth-inhibitory zone around the β-lactam disk 
with boronic acid was ≥5 mm larger than the diam-
eter around the disk without boronic acid (18).
Production of carbapenemases of the class  A or 
class  B was confirmed by the combined disk-test 
using meropenem disks with PBA and EDTA 
(ethylenediaminetetraacetic acid) (Sigma-Aldrich, 
Steinheim, Germany), respectively (19). Three 
meropenem (MEM) disks were placed on Mueller-
Hinton agar plate inoculated with the test strain. 
Ten µL of EDTA (300  mg) and PBA (300  mg) 
was added on the first and third disks, respec-
tively. The difference of ≥5  mm in the zone size 
between the disks with and without EDTA was 
suggesting the production of carbapenemase 
class B, and the difference of ≥5 mm in the zone 
size between the disks with and without PBA 
was suggesting  the  production of carbapenemase 
class A (19).
RESULTS
From December 2009 until May 2010, 3532 sam-
ples (out of 16037, 22%) were bacteria-posi-
tive. Gram-negative bacteria were isolated from 
2857  (80.9%) samples, out of which 184  (6.4%) 
phenotypically were ESBL/AmpC-producing 
bacteria. Among these, 33.7%, 27.8%, 14.1%, 
10.9%, 8.7%, 2.7%, 1.6%, 0.5%, and 0.5% were 
E. coli, Klebsiella spp., Citrobacter spp., Proteus 
spp., Enterobacter cloacae, Pseudomonas aerugi-
nosa, Morganella morganii, Providencia rettgeri, and 
Acinetobacter spp., respectively.
Among the ESBL/AmpC- producing isolates from 
the clinical outpatient samples, 143  (77.7%) were 
isolated from urines, 26  (14.1%) from surgical 
wounds, and 6 (3%) from other samples (skin and 
soft tissue infections [SSTIs], upper respiratory 
tract, ear swabs, genital tract, and eyes). Forty-five 
beta-lactamase-producing isolates were used for sus-
ceptibility testing.
From December 2013 until May 2014, 6279 envi-
ronmental samples were collected, out of which 
1141 were from water, 2405 from food, and 2733 
from environmental surfaces. In this group, out 
of 381 Gram-negative bacteria, 52  (13.6%) were 
ESBL/AmpC-producing isolates. Among these, 
37  (71.2%) were isolated from water, 7  (13.5%) 
from food, and 8 (15.4%) from environmental sur-
faces. The most prevalent ESBL/AmpC-producing 
bacteria isolated from environmental samples were 
E. coli (from 26  samples), Klebsiella spp. (10), 
non-fermenters (9), and other bacteria isolated from 
7 samples.
Antibiotic susceptibility patterns of the 
clinical isolates
Table  1 demonstrates the antimicrobial resistance 
results of 45 phenotypically positive beta-lactamase 
producing isolates of which 19 were E. coli isolates, 
17 were Klebsiella pneumonia, and 9 were Klebsiella 
oxytoca. The overall resistance of the isolates to the 
antibiotics demonstrated high resistance to amoxicil-
lin (100%), cefazolin (100%), cefuroxime (100%), 
ceftazidime (≈85%), cefoxitin (≈80%), ceftriaxone 
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(≈70%), gentamicin (≈70%), cefotaxime (≈65%), 
ciprofloxacin (≈60%) and, cefepime (≈40%), while 
the resistance to imipenem and meropenem was low.
Antibiotic susceptibility patterns of the 
isolates from environmental samples
Table  2 demonstrates the antimicrobial resistance 
results of 52 phenotypically positive beta-lact-
amase-producing isolates, out of which 26 were 
E. coli isolates, 10 Klebsiella spp., 9 non-fermenters, 
and 7 were from other isolates (4 Citrobacter spp. 
and 3 Enterobacter spp.).
Cefoxitin, cefpodoxime, aztreonam, and cefuroxime 
resistance in E. coli were 100%, 80%, 76.9%, and 
65.4%, respectively, while cefotaxime, cefepime, 
and ceftazidime resistance rates were lower (34.6%, 
23.1%, and 19.2% of cases). Carbapenem resistance 
was found in one E. coli isolate.
Cephalosporins resistance rates were high in 
Klebsiella spp., following were the rates in E. coli. 
The bacteria showed 20  -  100% overall resistance 
rates, and all Klebsiella spp. isolates were susceptible 
to imipenem and meropenem (Table 2).
Non-fermenters and other isolates showed higher 
resistance rates to the 3rd  and 4th  generations of 
cephalosporins compared to E. coli and Klebsiella 
spp. (Table 2).
DISCUSSION
This study aimed to determine variability in the 
prevalence of ESBL-producing isolates causing 
infections in humans, and ESBL-producing isolates 
from environmental samples such as food, water, 
and environmental surfaces.
Detection of the ESBL production was performed 
with the combined disk method and showed that 
6.5% of the clinical isolates were considered as 
potential producers of ESBLs, which was lower 
than in the reports from Serbia, the Republic of 
Macedonia, Turkey, and Egypt (20,21). However, 
our results are similar to those reported for Austria, 
Croatia, Slovenia, Japan, and Tunis (20,22,23).
The phenotypic cefoxitin resistance test showed a 
higher prevalence (70%) of the production of AmpC 
beta-lactamases which is contradictory to the report 
from Morocco (24), but similar to the report from the 
TABLE 1. Antimicrobial resistance of beta‑lactamase‑producing isolates collected from clinical outpatient samples
Causative 
agent isolated
Setting Number 
of isolates 
tested
Number (%) of antimicrobial resistance of various antibiotics*
AMX AMC CZ CXM CAZ CTX CRO FOX FEP IMI MEM GEN CIP PIP TZB
Escherichia 
coli
Outpatients 19 100 43.8 100 100 77.8 66.7 76.5 83.3 33.3 0 0 68.8 66.7 78.6 6.7
Klebsiella 
oxytoca
Outpatients 9 100 100 100 100 88.9 66.7 75 87.5 33.3 0 0 66.7 55.6 100 33.3
Klebsiella 
pneumoniae
Outpatients 17 100 90 80 100 88.2 64.7 58.8 58.8 52.9 0 0 88.2 52.9 58.8 5.9
*AMX: Amoxicillin, AMC: Amoxicillin/clavulanate, CZ: Cefazolin, CXM: Cefuroxime, CAZ: Ceftazidime, CTX: Cefotaxime, 
CRO:  Ceftriaxone, FOX: Cefoxitin, FEP: Cefepime, IPM: Imipenem, MEM: Meropenem, GEN: Gentamicin, CIP: Ciprofloxacin, 
PIP:  Piperacilin, TZB: Tazobactam
TABLE 2. Antimicrobial resistance of beta‑lactamase‑producing isolates collected from environmental samples
ESBL‑producing 
isolates
Total number 
of isolates
% Of antimicrobial resistance of various antibiotics*
AMC ATM CXM CAZ FOX CTX FEP IMP MEM CPD
Escherichia coli 26 84.6 76.9 65.4 19.2 100 34.6 23.1 3.8 3.8 80
Klebsiella spp. 10 100 90 90 20 100 30 30 0 0 57.1
Non‑fermenters 9 88.9 55.6 88.9 33.3 77.8 44.4 44.4 0 0 75
Others 7 100 100 71.4 57.1 100 42.9 42.9 0 28.6 66.7
*AMC: Amoxicillin/clavulanate, ATM: Aztreonam, CXM: Cefuroxime, CAZ: Ceftazidime, FOX: Cefoxitin, CTX: Cefotaxime, 
FEP:  Cefepime, IPM: Imipenem, MEM: Meropenem, CPD: Cefpodoxime; ESBL: Extended‑spectrum beta‑lactamase
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Netherlands (25). The number of potential producers 
of ESBLs and AmpC beta-lactamases in the isolates 
from the environmental samples was higher (13.6%) 
than in the isolates from the clinical outpatient sam-
ples, which is in agreement with the report from 
India (26). Patternel et al. reported a higher prevalence 
of ESBL-producing E. coli isolates from minced meat 
in 24% cases, in Graz, Austria, (13). Similarly, investi-
gators from the Netherlands reported 55% of ESBL-
producing E. coli isolates collected from retail chicken 
meat and surface water (14) and 100% from wastewa-
ter samples (27), which is contradictory to our report.
The ESBL-producing outpatient clinical isolates 
showed high rates of resistance to all cephalospo-
rins, except to cefepime and high rates of resistance 
to aminoglycosides and fluoroquinolones, similar 
to the reports from India and Pakistan (28,29). In 
2014, the World Health Organization reported that 
E. coli/K. pneumoniae was resistant to the 3rd genera-
tion of cephalosporins in 9.1/13.3% cases (Austria), 
21.3/82.1% (Serbia), 8.8/30.2% (Slovenia), and 
47.4/91% (the Republic of Macedonia) among oth-
ers (20). In some instances, these results are similar to 
ours, however there are some differences as well. For 
the treatment of these infections in the community, 
first-line antibiotics were gentamicin or ciprofloxa-
cin (cheap antibiotics without medical prescription), 
and this is similar to the report from Pakistan (29).
All isolates from our environmental samples showed 
high resistance rates to cefoxitin, cefuroxime, azt-
reonam, and amoxicillin/clavulanic acid, but low 
resistance to the 3rd and 4th generations of cephalo-
sporins, which is also reported in Egypt (21).
Resistant bacteria can cause foodborne diseases, at 
first a silent carrier state but later may cause infec-
tions that are not recognized as being of foodborne 
origin. ESBL-producing isolates could be transmit-
ted by the food production chain and environmen-
tal samples (30).
Boonyasiri et al. reported that basic sanitation and 
hygiene, including consumption of cooked food 
and clean water, as well as hand washing, are very 
important measures for containment and preven-
tion of antibiotic resistance (30).
The main limitation of this study is the small number 
of ESBL-producing isolates that were collected/avail-
able for the analysis, because of the short time span (six 
months) and due to analysis of only one region-Can-
ton, out of ten cantons in Bosnia and Herzegovina. 
It is not representative for whole B&H, because we 
have a different number of populations in each can-
ton, different lifestyles with different social conditions, 
different climate, etc. However, reduced susceptibility 
of these isolates is a worldwide concern. Because of 
the high prevalence of the resistant ESBL-producing 
strains in the epidemiologically unrelated patients and 
environmental samples in this study, further local sur-
veillance is needed. Molecular characterization, or at 
least phenotypic testing of the ESBL production of 
Gram-negative bacteria, is important for appropriate 
therapy and the detection of the sources and modes of 
the spread, which is further the main step in designing 
targeted infection control strategies.
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